title: [The use of Sandostatin in the combined treatment of surgical diseases of the pancreas].
abstract: The paper analyzes experience gained with the use of Sandostatin in patients with a surgical operation-induced pathology of pancreas. Sandostatin is known to be capable of suppressing the exocrine activity of pancreas, which fact made for decline in the recordable postoperative complications and improvement of results of surgical treatment. The maiden experience gained with its use showed high efficacy of Sandostatin in a multimodality treatment of patients presenting with surgical pathology of pancreas.
authors.forename: V F
authors.initials: VF
authors.lastname: Saenko
authors.forename: Iu Z
authors.initials: IuZ
authors.lastname: Lifshits
authors.forename: S P
authors.initials: SP
authors.lastname: Kozhara
authors.forename: A Iu
authors.initials: AIu
authors.lastname: Usenko
authors.forename: S A
authors.initials: SA
authors.lastname: Andreeshchev
authors.forename: V V
authors.initials: VV
authors.lastname: Kryzhevskiĭ
authors.forename: V V
authors.initials: VV
authors.lastname: Olenin
authors.forename: O A
authors.initials: OA
authors.lastname: Beliaeva
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D004341:Drug Evaluation; D006801:Humans; D007340:Insulinoma / Q000188:drug therapy* / Q000601:surgery; D015282:Octreotide / Q000627:therapeutic use*; D010179:Pancreas / Q000187:drug effects / Q000378:metabolism; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000601:surgery; D011183:Postoperative Complications / Q000517:prevention & control
chemical_list: D018931:Antineoplastic Agents, Hormonal; D015282:Octreotide